NovaBay Pharmaceuticals to Hold 2019 Fourth Quarter and Full Year Conference Call on March 26, 2020
March 19 2020 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing Avenova® for
the domestic eye care market, announces that it will report 2019
fourth quarter and full year financial results after market close
on Thursday, March 26, 2020 and will hold an investment community
conference call that day.
DATE:
Thursday, March 26
TIME:
4:30 p.m. ET / 1:30 p.m. PT
DIAL IN:
800-608-8202 from within the U.S.
702-495-1913 from outside the U.S.
Enter conference identification number
5299253
The live call also will be available at
http://novabay.com/investors/events. A replay of the call will be
available beginning two hours after its completion through 11:59
p.m. Eastern time April 13, 2020, by dialing 855-859-2056 from
within the U.S. or 404-537-3406 from outside the U.S. and entering
the conference identification number 5299253. The call will also be
archived at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, CELLERX® for the aesthetic
dermatology market and NEUTROPHASE® for the wound care market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Socialize and Stay informed on
NovaBay’s progress: Like us on Facebook Follow us
on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200319005017/en/
NovaBay Contact Justin Hall,
President and Chief Executive Officer 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
